Performance monitoring is the ongoing review of a tool's behavior after deployment. For healthcare AI, monitoring may include accuracy, workflow fit, false positives, false negatives, drift, user overrides, incidents, and population-level differences.
Buyers should define owners, metrics, review cadence, thresholds, and rollback procedures before production use.
Application scenario: In workflow review, this term helps teams map a vendor claim to the care setting, data flow, integration point, user handoff, and oversight step where it applies. Procurement impact: Buyers should evaluate evidence, interoperability effort, security and privacy controls, pricing assumptions, support, and compliance responsibilities before shortlisting or contracting for a tool that depends on this capability.
Sources and review notes
These links support definition-level research and do not establish the regulatory status, safety, or suitability of any product.
NIST's voluntary AI Risk Management Framework treats monitoring as continuous lifecycle risk management rather than a single accuracy check, with testing before deployment and regularly during operation. NIST's 2026 report separates post-deployment monitoring into functionality, operational, human-factors, security, compliance, and large-scale-impact categories; it also identifies unresolved barriers including performance degradation and drift, fragmented logging, scaling human review, and the lack of mature shared methods, so it does not establish a universal metric, cadence, or threshold. FDA transparency and Good Machine Learning Practice materials call for intended-use and workflow context, performance and limitation disclosure, error and degradation detection, ongoing monitoring, change management, and a total-product-lifecycle approach, but those materials address regulated machine-learning-enabled medical devices and do not determine obligations for every healthcare AI product. WHO's guidance applies specifically to large multimodal or generative models in health and recommends that governments introduce independent post-release audits and impact assessments for large-scale deployments; its concerns include inaccurate, biased, or incomplete output, automation bias, privacy, cybersecurity, and unequal impacts. These sources do not validate a vendor, certify safety or compliance, or define one sufficient dashboard. Drift is only one performance signal. A monitoring plan should identify the intended use, deployment version, baseline, denominator, outcome or ground-truth source and its delay, target and guardrail, sample size and uncertainty, site and population strata, owner, review cadence, alert severity, investigation clock, and stop, fallback, rollback, revalidation, and communication authority. Teams should separately monitor input quality, availability and latency, output quality, calibration and discrimination when applicable, false positives and negatives, abstentions, overrides and reliance, downstream actions, incidents, equity, privacy and security events, workflow burden, support signals, and vendor, model, data, or configuration changes. Model metrics should be distinguished from human-AI team performance, service reliability, clinical or operational outcomes, and business outcomes. Evidence should preserve versioned inputs, outputs, context, adjudication, and actions; alerts require qualified review, and changes should be tested through shadow, staged, or otherwise controlled validation before broad release.
